Actively Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Led by Novartis Pharmaceuticals · Updated on 2026-04-20
240
Participants Needed
103
Research Sites
320 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
CONDITIONS
Official Title
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive ANA test or positive anti-dsDNA test at screening
- Active biopsy-confirmed lupus nephritis Class III or IV, with or without Class V, within 3 months prior to screening
- Active kidney disease requiring corticosteroids combined with MMF or MPS at screening
- Estimated glomerular filtration rate (eGFR) of at least 30 ml/min/1.73 m2
- Vaccinated against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae
- Receiving supportive care including stable doses of anti-malarials, ACE inhibitors or ARBs at screening
- First presentation or flare of lupus nephritis
You will not qualify if you...
- Induction treatment with cyclophosphamide within 3 months before planned study treatment
- Treatment with calcineurin inhibitors within 3 months prior to randomization
- Rapidly progressive glomerulonephritis defined by 50% decline in eGFR within 3 months before screening
- Renal biopsy showing more than 50% interstitial fibrosis/tubular atrophy or glomerulosclerosis or judged unlikely to respond to immunosuppressive therapy
- Taking systemic corticosteroids over 5 mg/day prednisone equivalent for conditions other than SLE or lupus nephritis
- For SLE or lupus nephritis, corticosteroid use exceeding average 15 mg/day prednisone equivalent in past 4 weeks or 30 mg/day in past week
- Receipt of more than 1000 mg total dose of intravenous methylprednisolone pulses within 2 weeks prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 103 locations
1
AKDHC Medical Research ServicesLLC
Phoenix, Arizona, United States, 85016
Withdrawn
2
Kaiser Permanente Fontana
Fontana, California, United States, 92335
Withdrawn
3
Univ Calif Irvine
Irvine, California, United States, 92697
Active, Not Recruiting
4
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States, 90095
Actively Recruiting
5
Loma Linda University
San Bernardino, California, United States, 92408
Active, Not Recruiting
6
Olive View UCLA Medical Center
Sylmar, California, United States, 91342
Active, Not Recruiting
7
University of Colorado Denver
Aurora, Colorado, United States, 80045
Actively Recruiting
8
Royal Research Corp
Hollywood, Florida, United States, 33021
Actively Recruiting
9
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
Actively Recruiting
10
Nephrology Associates Of Central FL
Orlando, Florida, United States, 32806
Active, Not Recruiting
11
Florida Kidney Physicians
Riverview, Florida, United States, 33578
Actively Recruiting
12
Florida Kidney Physicians
Riverview, Florida, United States, 33578
Actively Recruiting
13
Nep Assoc of Northern Illinois
Hinsdale, Illinois, United States, 60521
Active, Not Recruiting
14
Wichita Community Clcl Onco Program
Wichita, Kansas, United States, 67214
Actively Recruiting
15
Ochsner Health System
New Orleans, Louisiana, United States, 70121
Actively Recruiting
16
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Active, Not Recruiting
17
Brigham and Womens Hosp Harvard Med School
Boston, Massachusetts, United States, 02115
Actively Recruiting
18
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
Withdrawn
19
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Active, Not Recruiting
20
Stony Brook Internists PC
East Setauket, New York, United States, 11733
Actively Recruiting
21
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
22
Temple University
Philadelphia, Pennsylvania, United States, 19140
Actively Recruiting
23
Allegheny Health Network
Pittsburgh, Pennsylvania, United States, 15212
Withdrawn
24
Dallas Nephrology Associates
Dallas, Texas, United States, 75204
Active, Not Recruiting
25
Prolato Clinical Research Center
Houston, Texas, United States, 77054
Actively Recruiting
26
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
27
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina, 2000
Withdrawn
28
Novartis Investigative Site
San Luis, Argentina, 5700
Withdrawn
29
Novartis Investigative Site
Santa Fe, Argentina, S3000EPV
Active, Not Recruiting
30
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 40150 150
Active, Not Recruiting
31
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil, 30150-221
Completed
32
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil, 36010 570
Active, Not Recruiting
33
Novartis Investigative Site
Barretos, São Paulo, Brazil, 14784 400
Active, Not Recruiting
34
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 01308-050
Active, Not Recruiting
35
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 04038-002
Active, Not Recruiting
36
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 05403 000
Completed
37
Novartis Investigative Site
Salvador, Brazil, 40323-010
Active, Not Recruiting
38
Novartis Investigative Site
Nanning, Guangxi, China, 530022
Actively Recruiting
39
Novartis Investigative Site
Wuhan, Hubei, China, 430022
Actively Recruiting
40
Novartis Investigative Site
Shenyang, Liaoning, China, 110004
Actively Recruiting
41
Novartis Investigative Site
Yinchuan, Ningxia, China, 750004
Active, Not Recruiting
42
Novartis Investigative Site
Beijing, China, 100034
Active, Not Recruiting
43
Novartis Investigative Site
Shenzhen, China, 518036
Actively Recruiting
44
Novartis Investigative Site
Barranquilla, Atlántico, Colombia, 080020
Active, Not Recruiting
45
Novartis Investigative Site
Bogota, Cundinamarca, Colombia, 111411
Active, Not Recruiting
46
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia, 680003
Active, Not Recruiting
47
Novartis Investigative Site
Montería, Colombia, 230004
Active, Not Recruiting
48
Novartis Investigative Site
Marseille, France, 13005
Completed
49
Novartis Investigative Site
Nantes, France, 44093
Actively Recruiting
50
Novartis Investigative Site
Paris, France, 75015
Withdrawn
51
Novartis Investigative Site
Strasbourg, France, 67091
Withdrawn
52
Novartis Investigative Site
Munich, Bavaria, Germany, 81377
Withdrawn
53
Novartis Investigative Site
Ludwigshafen, Germany, Germany, 67063
Withdrawn
54
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany, 60590
Withdrawn
55
Novartis Investigative Site
Braunschweig, Lower Saxony, Germany, 38126
Actively Recruiting
56
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany, 51109
Actively Recruiting
57
Novartis Investigative Site
Berlin, Germany, 13353
Withdrawn
58
Novartis Investigative Site
Mainz, Germany, 55131
Actively Recruiting
59
Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong, 999077
Active, Not Recruiting
60
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary, 4032
Withdrawn
61
Novartis Investigative Site
Budapest, Hungary, H-1083
Withdrawn
62
Novartis Investigative Site
Szeged, Hungary, 6725
Withdrawn
63
Novartis Investigative Site
Ahmedabad, Gujarat, India, 380015
Withdrawn
64
Novartis Investigative Site
Kozhikode, Kerala, India, 673008
Actively Recruiting
65
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India, 110029
Actively Recruiting
66
Novartis Investigative Site
Vellore, Tamil Nadu, India, 632 004
Withdrawn
67
Novartis Investigative Site
Hyderabad, Telangana, India, 500082
Actively Recruiting
68
Novartis Investigative Site
Lucknow, Uttar Pradesh, India, 226014
Actively Recruiting
69
Novartis Investigative Site
Puducherry, India, 607402
Withdrawn
70
Novartis Investigative Site
Ashkelon, Israel, 7830604
Withdrawn
71
Novartis Investigative Site
Jerusalem, Israel, 9112001
Withdrawn
72
Novartis Investigative Site
Ramat Gan, Israel, 5265601
Withdrawn
73
Novartis Investigative Site
Kuantan, Pahang, Malaysia, 25100
Actively Recruiting
74
Novartis Investigative Site
Taiping, Perak, Malaysia, 34000
Actively Recruiting
75
Novartis Investigative Site
Selangor Darul Ehsan, Malaysia, 68100
Actively Recruiting
76
Novartis Investigative Site
Tampico, Tamaulipas, Mexico, 89440
Active, Not Recruiting
77
Novartis Investigative Site
Mérida, Yucatán, Mexico, 97070
Active, Not Recruiting
78
Novartis Investigative Site
Aguascalientes, Mexico, 20230
Completed
79
Novartis Investigative Site
Veracruz, Mexico, 91900
Active, Not Recruiting
80
Novartis Investigative Site
Makati City, National Capital Region, Philippines, 1218
Actively Recruiting
81
Novartis Investigative Site
Iloilo City, Philippines, 5000
Withdrawn
82
Novartis Investigative Site
Quezon, Philippines, 1102
Actively Recruiting
83
Novartis Investigative Site
Carnaxide, Portugal, 2799-523
Active, Not Recruiting
84
Novartis Investigative Site
Coimbra, Portugal, 3004-561
Active, Not Recruiting
85
Novartis Investigative Site
Lisbon, Portugal, 1649-035
Active, Not Recruiting
86
Novartis Investigative Site
Porto, Portugal, 4200 319
Withdrawn
87
Novartis Investigative Site
Vila Nova de Gaia, Portugal, 4434 502
Actively Recruiting
88
FDI Clinical Research
San Juan, Puerto Rico, 00927
Actively Recruiting
89
Novartis Investigative Site
Singapore, Singapore, Singapore, S308433
Actively Recruiting
90
Novartis Investigative Site
Port de Sagunt, Valencia, Spain, 46520
Withdrawn
91
Novartis Investigative Site
Barcelona, Spain, 08036
Active, Not Recruiting
92
Novartis Investigative Site
Ciudad Real, Spain, 13005
Actively Recruiting
93
Novartis Investigative Site
Madrid, Spain, 28034
Actively Recruiting
94
Novartis Investigative Site
Madrid, Spain, 28040
Actively Recruiting
95
Novartis Investigative Site
Seville, Spain, 41009
Active, Not Recruiting
96
Novartis Investigative Site
Ankara, Bilkent-Cankaya, Turkey (Türkiye), 06800
Active, Not Recruiting
97
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye), 34093
Active, Not Recruiting
98
Novartis Investigative Site
Kayseri, Melikgazi, Turkey (Türkiye), 38039
Active, Not Recruiting
99
Novartis Investigative Site
Bursa, Nilufer, Turkey (Türkiye), 16059
Actively Recruiting
100
Novartis Investigative Site
Ankara, Yenimahalle, Turkey (Türkiye), 06500
Active, Not Recruiting
101
Novartis Investigative Site
Mersin, Yenisehir, Turkey (Türkiye), 33110
Completed
102
Novartis Investigative Site
Cambridge, United Kingdom, CB2 0QQ
Active, Not Recruiting
103
Novartis Investigative Site
Leicester, United Kingdom, LE5 4PW
Withdrawn
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here